Retinal drugs market growth driven by aging population, rising AMD prevalence, and advances in ophthalmic drug delivery and retinal disease treatment innovation.

Eylea, developed by Regeneron, is the world’s leading treatment for age-related macular degeneration, a common cause of blindness in older adults. Since its launch in 2013, Eylea has become a major ...